Keros Therapeutics Inc   (KROS)
Other Ticker:  
Price: $30.4100 $0.81 2.736%
Day's High: $31.26 Week Perf: 0.16 %
Day's Low: $ 29.49 30 Day Perf: 8.53 %
Volume (M): 377 52 Wk High: $ 59.96
Volume (M$): $ 11,477 52 Wk Avg: $41.92
Open: $29.80 52 Wk Low: $27.02

 Market Capitalization (Millions $) 902
 Shares Outstanding (Millions) 30
 Employees 60
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -142
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 2

Keros Therapeutics Inc
Keros Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for rare genetic diseases characterized by a deficiency in specific proteins. Keros Therapeutics was founded in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics is primarily focused on developing small molecule therapeutics that can modulate the activity of protein targets known to play a critical role in human disease. The company's lead drug candidate, KER-050, is a potent and selective agonist of the erythropoietin receptor (EPOR). The EPOR is a crucial protein involved in the regulation of red blood cell production and survival. KER-050 is currently being evaluated in a Phase 2 clinical trial for treatment for patients with myelodysplastic syndromes (MDS) or myelofibrosis (MF) who are anemic and require red blood cell transfusions.

Keros Therapeutics' pipeline also includes several other drug candidates targeting various disease indications. These include KER-047, a small molecule inhibitor of secretion and TGF-' activation, which is being developed for treatment of fibrotic diseases; KER-012, a small molecule Modulator of the Transforming Growth Factor Beta (TGF-') Pathway, which is being developed for the treatment of certain fibrotic disorders and cancer; and KER-044, a small molecule activator of a protein that can enhance glucose uptake which is being developed for treatment of certain metabolic disorders, including Type 2 diabetes.

Keros Therapeutics is committed to leveraging its expertise in drug discovery and development to bring novel therapies to patients with unmet medical needs. To this end, the company employs cutting-edge technologies in protein engineering, structural biology, and computer-aided drug design to identify and optimize potential drug candidates. Keros has also established partnerships with academic and industry collaborators to expand its drug discovery capabilities and further augment its pipeline.

The company has a strong management team that includes experienced leaders from the biotech and pharmaceutical industries. Keros Therapeutics' CEO, Jasbir Seehra, has over 25 years of experience in biotech drug discovery and has previously served in leadership roles at Genentech, Inc. and Amgen Inc. The company's scientific co-founders, Drs. Avrum Spira and Benjamin Ebert, are both leading experts in their respective fields of genomics and hematology and have made significant contributions to academic research in these areas.

Overall, Keros Therapeutics is a promising biopharmaceutical company that is focused on developing novel drugs to treat rare genetic diseases where there are limited treatment options. With an experienced management team, promising pipeline, and strong partnerships, Keros Therapeutics is poised to make significant contributions to the advancement of precision medicine.

   Company Address: 1050 Waltham Street, Lexington, 2421 MA
   Company Phone Number: 314-6297   Stock Exchange / Ticker: NASDAQ KROS
   KROS is expected to report next financial results on March 02, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Lipocine Inc

the Major Pharmaceutical Preparations company in the fiscal time-frame ending September 30 2023

In its most recent fiscal period Lipocine Inc increased a shortfall per share at $-1.27 per share, opposite of $-0.03 per share a year before reporting season, In the prior reporting season LPCN realized $-0.68 per share.

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.

Briacell Therapeutics Corp

Briacell Therapeutics Corp Releases Fourth Quarter Fiscal Results - Showcasing Impressive Growth in Major Pharmaceutical Preparations Sector

The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.

Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.


Keros Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com